ArticleArchives of Razi Institute2025
Evaluation of Inflammatory Markers (PV, ESR, CRP) in the Early Diagnosis of Cancer and Their Relationship With Survival Rate.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study investigates the prevalence of cancer, compares inflammatory factors, and examines how inflammatory markers- C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and plasma viscosity (PV)-can aid in the early diagnosis of cancer in primary care settings. Materials & Methods: We included newly diagnosed patients of all types of malignancy (children and adults) in this retrospective study from 2018 to 2023. The results of CRP, ESR, PV tests, and demographic data (age, gender, type of malignancy, and survival) were collected. Research data were analyzed using the t-test and chi-square statistical methods. According to the results, the average ESR and PV were higher in patients who died than in those who survived (P<0.05). In addition, it was shown that there was a significant relationship between the age and gender of the patients and their survival (P<0.05). It was also shown that there was a significant relationship between the survival of patients with ESR, CRP, and PV across different cancers (P<0.05). On the other hand, a significant correlation was found between ESR, CRP, and PV among different cancers (P<0.05). Results: Based on the results, it was shown that the average ESR and PV were higher in patients who died than in those who survived (P<0.05). In addition, it was shown that there was a significant relationship between the age and gender of the patients and their survival (P<0.05). It was also shown that there was a significant relationship between the survival of patients and ESR, CRP and PV across different cancers (P<0.05). On the other hand, it was shown that there was a significant correlation between ESR, CRP and PV among different cancers (P<0.05). Conclusion: To halt the progression of acute inflammation to chronic inflammation and mitigate its harmful implications, it is essential to reduce the inflammatory response. Efficient management of inflammation is crucial in preventing patient mortality and is thus essential for the treatment and survival of patients with malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.